SCA
NVAX icon

Stonebridge Capital Advisors’s Novavax NVAX Stock Holding History

Stonebridge Capital Advisors’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10
Closed -$103 – 983
2022
Q4 		$103 Hold
10
– – ﹤0.01% 937
2022
Q3 		$0 Hold
10
– – ﹤0.01% 1083
2022
Q2 		$1K Hold
10
– – ﹤0.01% 879
2022
Q1 		$1K Hold
10
– – ﹤0.01% 977
2021
Q4 		$1K Hold
10
– – ﹤0.01% 923
2021
Q3 		$2K Buy
+10
New +$2.2K ﹤0.01% 831

Other funds holding NVAX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stonebridge Capital Advisors's NVAX Position: Q1 2023 in Review

Stonebridge Capital Advisors sold out of Novavax (NVAX) in Q1 2023, closing a stake of 10 shares — an estimated $103 sold.

Stonebridge Capital Advisors first reported a position in NVAX in Q3 2021 and held it in 6 quarters. The position peaked at $2K in Q3 2021. 222 funds tracked by Wall St. Rank hold NVAX as of Q1 2023.

  • Stonebridge Capital Advisors reported no remaining Novavax position as of Q1 2023 after selling out during the quarter.
  • Stonebridge Capital Advisors sold 10 Novavax shares in Q1 2023, an estimated $103.
  • Stonebridge Capital Advisors first reported a position in Novavax in Q3 2021 and held it in 6 quarters.
  • Stonebridge Capital Advisors's Novavax position peaked at $2K in Q3 2021.
  • 222 funds tracked by Wall St. Rank held Novavax as of Q1 2023.

Based on Stonebridge Capital Advisors's 13F filing for Q1 2023, filed 12 May 2023.